| NCT06282978 | PETHEMA Foundation | Multiple Myeloma in Relapse | 2023-11-23 | PHASE2 |
| NCT04798586 | Pfizer | Relapsed or Refractory Multiple Myeloma | 2021-03-22 | PHASE1 |
| NCT07247097 | Massachusetts General Hospital|Pfizer | Multiple Myeloma|Newly Diagnosed Multiple Myeloma|Transplant Ineligible|Newly Diagnosed Multiple Myeloma (NDMM) | 2026-04-15 | PHASE2 |
| NCT05927571 | Genentech, Inc. | Relapsed or Refractory Multiple Myeloma | 2023-08-10 | PHASE1 |
| NCT07280013 | C4 Therapeutics, Inc. | Multiple Myeloma (MM) | 2026-02-06 | PHASE1 |
| NCT05014412 | Pfizer | Multiple Myeloma | 2021-10-07 | PHASE2 |
| NCT06183489 | Stichting European Myeloma Network|Pfizer | Smoldering Multiple Myeloma | 2024-05-14 | PHASE2 |
| NCT06645678 | YOUNGIL KOH | Relapsed Refractory Multiple Myeloma (RRMM) | 2024-11-26 | PHASE1|PHASE2 |
| NCT07474961 | Anne Louise T?lb?ll S?rensen | Waldenstrom Macroglobulinaemia|Multiple Myeloma | 2027-03 | PHASE4 |
| NCT06215118 | Pfizer|Bristol-Myers Squibb | Multiple Myeloma | 2024-02-20 | PHASE1 |
| NCT07382739 | M.D. Anderson Cancer Center|Pfizer | Phase 2|Radiotherapy-Induced Immune Priming|Elranatamab|Relapsed Refractory Multiple Myeloma (RRMM)|Extramedullary Disease in Multiple Myeloma|Paramedullary Disease|PMD | 2026-03-31 | PHASE2 |
| NCT05228470 | Pfizer | Elranatamab|Myeloma|Multiple Myeloma|Relapsed Multiple Myeloma|Refractory Multiple Myeloma|PF-06863135|BCMA|Bispecific|Bispecific Antibody|BCMA-CD3 Bispecific|MagnetisMM-8 | 2021-12-21 | PHASE2 |
| NCT05238311 | Pfizer | Multiple Myeloma | | |
| NCT05623020 | Pfizer | Multiple Myeloma | 2022-11-10 | PHASE3 |
| NCT06832865 | Massachusetts General Hospital|Pfizer|Sanofi | Relapsed Refractory Multiple Myeloma (RRMM)|Relapsed Refractory Multiple Myeloma | 2025-08-14 | PHASE2 |
| NCT06152575 | Pfizer | Multiple Myeloma | 2024-02-08 | PHASE3 |
| NCT06569147 | Brigham and Women´s Hospital | AL Amyloidosis | 2024-11-01 | PHASE1|PHASE2 |
| NCT06918002 | Intergroupe Francophone du Myelome|Pfizer | Multiple Myeloma, Newly Diagnosed | 2025-07-09 | PHASE3 |
| NCT06504524 | Pfizer | Multiple Myeloma | 2023-09-01 | |
| NCT05317416 | Pfizer | Multiple Myeloma | 2022-03-25 | PHASE3 |
| NCT07320326 | Peking University People´s Hospital|Pfizer | TCE-RRMM | 2025-12-30 | |
| NCT05675449 | Pfizer | Multiple Myeloma | 2022-12-14 | PHASE1 |
| NCT06581848 | Pfizer | Multiple Myeloma | 2025-06-05 | |
| NCT06359067 | Assistance Publique - H?pitaux de Paris | Multiple Myeloma | 2022-07-01 | |
| NCT06974786 | SCRI Development Innovations, LLC|Pfizer|coMMit, Myeloma Trials, Innovated | Multiple Myeloma, Newly Diagnosed|Multiple Myeloma (MM) | 2025-08-08 | PHASE2 |
| NCT05020236 | Pfizer | Multiple Myeloma | 2021-10-04 | PHASE3 |
| NCT06106945 | AstraZeneca | Multiple Myeloma | 2023-12-05 | PHASE1|PHASE2 |
| NCT06988488 | Celgene | Multiple Myeloma | 2025-10-07 | PHASE1|PHASE2 |
| NCT06997081 | University of Miami|Pfizer | Multiple Myeloma | 2025-09-16 | PHASE2 |
| NCT06592222 | Pfizer | Multiple Myeloma | 2024-08-26 | |
| NCT06799026 | David Avigan|Pfizer | Multiple Myeloma|Relapse Multiple Myeloma|Refractory Multiple Myeloma | 2025-01-31 | PHASE1 |
| NCT04068597 | CellCentric Ltd. | Haematological Malignancy|Acute Myeloid Leukemia|Non Hodgkin Lymphoma|Multiple Myeloma|Higher-risk Myelodysplastic Syndrome|Peripheral T Cell Lymphoma | 2019-08-09 | PHASE1|PHASE2 |
| NCT05565391 | Pfizer | Multiple Myeloma | 2022-10-03 | |
| NCT06855121 | St. Olavs Hospital|Norwegian University of Science and Technology|Haukeland University Hospital|Helse Stavanger HF|Oslo University Hospital|University Hospital, Akershus|Sykehuset i Vestfold Hospital Trust|University Hospital of North Norway|?lesund Hospital, Norway|Helse Nord-Tr?ndelag HF|Sorlandet Hospital HF|F?rde Hospital Trust|Molde Hospital|Bod? Hospital, Norway|Helse Fonna|Volda Hospital|Diakonhjemmet Hospital|Telemark Hospital Trust|Kristiansund Hospital|Vestre Viken Hospital Trust|Lovisenberg Diakonale Hospital|Sykehuset Innlandet HF | Myeloma Multiple|Plasma Cell Leukemia|AL Amyloidosis | 2025-01-15 | |
| NCT06711705 | University of California, San Diego | Multiple Myeloma | 2024-12-18 | PHASE2 |
| NCT05932290 | Pfizer | Multiple Myeloma | 2023-06-01 | |
| NCT06015542 | Thomas Lund|Pfizer|Vejle Hospital | Multiple Myeloma | 2025-01-29 | PHASE2 |
| NCT06947083 | H. Lee Moffitt Cancer Center and Research Institute|Pfizer | Myeloma | 2025-05-27 | PHASE2 |
| NCT06421675 | Ontario Clinical Oncology Group (OCOG)|Pfizer|McMaster University | Refractory Multiple Myeloma | 2025-03-28 | PHASE2 |
| NCT06057402 | Pfizer | Multiple Myeloma | 2023-10-03 | PHASE4 |
| NCT06138275 | Massachusetts General Hospital|Pfizer | Refractory Multiple Myeloma|Relapse Multiple Myeloma|Multiple Myeloma | 2024-03-08 | PHASE2 |
| NCT06121843 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Multiple Myeloma | 2024-02-22 | PHASE1 |
| NCT06931704 | Nantes University Hospital | Multiple Myeloma | 2025-05-01 | PHASE2 |
| NCT05090566 | Pfizer | Multiple Myeloma | 2021-10-27 | PHASE2 |
| NCT06207799 | M.D. Anderson Cancer Center|Pfizer | Multiple Myeloma|Post-transplant MRD-guided Maintenance Therapy|Pre-transplant Purging | 2024-07-17 | PHASE2 |